Time spent at health facility is a key driver of patient satisfaction, but did not influence retention to HIV care: A serial cross-sectional study in Mozambique.

INTRODUCTION: Patient satisfaction with clinical services can have an effect on retention in HIV care and adherence to antiretroviral therapy. This study assessed patient satisfaction and its association with retention and viral suppression in Zambézia Province, Mozambique. METHODS: Monthly exit interviews with persons living with HIV were completed from August 2017-January 2019 in 20 health facilities; clinical data were extracted from medical records. Regression analyses assessed the effect of satisfaction scores on retention and viral suppression, adjusting for age, sex, education, civil status, time on treatment, and site. Satisfaction scores were correlated with time spent at health facilities using generalized linear regression models. RESULTS: Data from 4388 patients were analyzed. Overall median satisfaction score was 75% (IQR 53%-84%); median time spent at facilities (from arrival until completion of clinical services) was 2h54min (IQR 1h48min-4h). Overall satisfaction score was not associated with higher odds of retention or viral suppression, but association was seen between satisfaction regarding attention given to patient and respect and higher odds of viral suppression. Patient satisfaction was negatively associated with time spent in facility (Spearman's correlation -0.63). Increased time spent at facility (from 1 to 3 hours) was not associated with lower retention in care (OR 0.72 [95%CI:0.52-1.01] and 0.83 [95%CI: 0.63-1.09] at 6- and 12-months, respectively), nor with a lower odds of viral suppression (OR 0.96 [95%CI: 0.71-1.32]). CONCLUSIONS: Strategies to reduce patient wait times at the health facility warrant continued prioritization. Differentiated models of care have helped considerably, but novel approaches are still needed to further decongest crowded health facilities. In addition, a good client-provider communication and positive attitude can improve patient satisfaction with health services, with an overall improved retention.

The effect of a Mentor Mothers program on prevention of vertical transmission of HIV outcomes in Zambézia Province, Mozambique: a retrospective interrupted time series analysis.

INTRODUCTION: Mentor Mothers (MM) provide peer support to pregnant and postpartum women living with HIV (PPWH) and their infants with perinatal HIV exposure (IPE) throughout the cascade of prevention of vertical transmission (PVT) services. MM were implemented in Zambézia Province, Mozambique starting in August 2017. This evaluation aimed to determine the effect of MM on PVT outcomes. METHODS: A retrospective interrupted time series analysis was done using routinely collected aggregate data from 85 public health facilities providing HIV services in nine districts of Zambézia. All PPWH (and their IPE) who initiated antiretroviral therapy (ART) from August 2016 through April 2019 were included. Outcomes included the proportion per month per district of: PPWH retained in care 12 months after ART initiation, PPWH with viral suppression and IPE with HIV DNA PCR test positivity by 9 months of age. The effect of MM on outcomes was assessed using logistic regression. RESULTS: The odds of 12-month retention increased 1.5% per month in the pre-MM period, compared to a monthly increase of 7.6% with-MM (35-61% pre-MM, 56-72% with-MM; p < 0.001). The odds of being virally suppressed decreased by 0.9% per month in the pre-MM period, compared to a monthly increase of 3.9% with-MM (49-85% pre-MM, 59-80% with-MM; p < 0.001). The odds of DNA PCR positivity by 9 months of age decreased 8.9% per month in the pre-MM period, compared to a monthly decrease of 0.4% with-MM (0-14% pre-MM, 4-10% with-MM; p < 0.001). The odds of DNA PCR uptake (the proportion of IPE who received DNA PCR testing) by 9 months of age were significantly higher in the with-MM period compared to the pre-MM period (48-100% pre-MM, 87-100% with-MM; p < 0.001). CONCLUSIONS: MM services were associated with improved retention in PVT services and higher viral suppression rates among PPWH. While there was ongoing but diminishing improvement in DNA PCR positivity rates among IPE following MM implementation, this might be explained by increased uptake of HIV testing among high-risk IPE who were previously not getting tested. Additional efforts are needed to further optimize PVT outcomes, and MM should be one part of a comprehensive strategy to address this critical need.

Monitoring Pharmacy and Test Kit Stocks in Rural Mozambique: U.S. President's Emergency Plan for AIDS Relief Surveillance to Help Prevent Ministry of Health Shortages.

Support of human immunodeficiency virus (HIV) and tuberculosis (TB) testing and treatment supported by President's Emergency Plan for AIDS Relief (PEPFAR) in Africa requires immense quantities of tests and medications. We sought to use central pharmacy supply data of Mozambique's rural Zambézia Province (2017 population ≈5.11 million persons; ≈12.6% adult HIV prevalence in 2016) to examine shortages, stockouts, and trends in availability. Using stock surveillance for 60 weeks in 2014-2015, we assessed availability of 36 medications [4 classes: adult antiretroviral (ARV) medications, pediatric ARVs, anti-TB medications, and antibiotics] and diagnostic test kits (2 rapid tests for HIV; 1 each for malaria and syphilis). We contrasted these to 2018-2019 data. We modeled pharmacy data using ordinal logistic regression, characterizing weekly product availability in four categories: good, adequate, shortage, or complete stockout. We found 166 (7.7%) stockouts and 150 (6.9%) shortages among 2,160 weekly records. Earlier calendar time was associated with reduced medication supplies (p < .001). Certain medication/test kit classes were associated with reduced supply (p < .001). We found an interaction between time and medication class on the odds of reduced supply (p < .001). Pediatric ARVs had a 17.4 (95% confidence interval: 8.8-34.4) times higher odds of reduced medication supply compared with adult ARVs at study midpoint. Trends comparing the first and last weeks showed adult ARVs having 67% and pediatric having 71% lower odds of reduced supplies. Only adult ARV shortages improved amid growing demand. Data from 2018 to 2019 suggest continuing inventory management challenges. Monitoring of drug (especially pediatric) and test kit shortages is vital to ensure quality improvement to guarantee adequate supplies to enable patients and care providers to achieve sustained viral suppression. A central Mozambican drug repository in the nation's second largest Province continues to experience drug and rapid test kit stockouts.

Immunodeficiency at Antiretroviral Therapy Start: Five-Year Adult Data (2012-2017) Based on Evolving National Policies in Rural Mozambique.

Before the 2015 implementation of "Test and Start," the initiation of combination antiretroviral therapy (ART) was guided by specific CD4 cell count thresholds. As scale-up efforts progress, the prevalence of advanced HIV disease at ART initiation is expected to decline. We analyzed the temporal trends in the median CD4 cell counts among adults initiating ART and described factors associated with initiating ART with severe immunodeficiency in Zambézia Province, Mozambique. We included all HIV-positive, treatment-naive adults (age ≥ 15 years) who initiated ART at a Friends in Global Health (FGH)-supported health facility between September 2012 and September 2017. Quantile regression and multivariable logistic regression models were applied to ascertain the median change in CD4 cell count and odds of initiating ART with severe immunodeficiency, respectively. A total of 68,332 patients were included in the analyses. The median change in CD4 cell count under "Test and Start" was higher at +68 cells/mm3 (95% CI: 57.5-78.4) compared with older policies. Younger age and female sex (particularly those pregnant/lactating) were associated with higher median CD4 cell counts at ART initiation. Male sex, advanced age, WHO Stage 4 disease, and referrals to the health facility through inpatient provider-initiated testing and counseling (PITC) were associated with higher odds of initiating ART with severe immunodeficiency. Although there were reassuring trends in increasing median CD4 cell counts with ART initiation, ongoing efforts are needed that target universal HIV testing to ensure the early initiation of ART in men and older patients.

Partners-based HIV treatment for seroconcordant couples attending antenatal and postnatal care in rural Mozambique: A cluster randomized trial protocol.

BACKGROUND: In resource-limited rural settings, scale-up of services to eliminate mother-to-child transmission of HIV has not been as effective as in better resourced urban settings. In sub-Saharan Africa, women often require male partner approval to access and remain engaged in HIV care. Our study will evaluate a promising male engagement intervention ("Homens para Saúde Mais" (HoPS+) [Men for Health Plus]) targeting the elimination of mother-to-child transmission in rural Mozambique. DESIGN: We will use a cluster randomized clinical trial design to engage 24 health facilities (12 intervention and 12 standard of care), with 45 HIV-infected seroconcordant couples per clinic. The planned intervention will engage male partners to address social-structural and cultural factors influencing eMTCT based on new couple-centered integrated HIV services. CONCLUSIONS: The HoPS+ study will evaluate the effectiveness of engaging male partners in antenatal care to improve outcomes among HIV-infected pregnant women, their HIV-infected male partners, and their newborn children. Our objectives are to: (1) Implement and evaluate the impact of male-engaged, couple-centered services on partners' retention in care, adherence to antiretroviral therapy, early infant diagnosis uptake, and mother-to-child transmission throughout pregnancy and breastfeeding; (2) Investigate the impact of HoPS+ intervention on hypothesized mechanisms of change; and (3) Use validated simulation models to evaluate the cost-effectiveness of the HoPS+ intervention with the use of routine clinical data from our trial. We expect the intervention to lead to strategies that can improve outcomes related to partners' retention in care, uptake of services for HIV-exposed infants, and reduced MTCT.

The effect of a Mentor Mothers program on prevention of vertical transmission of HIV outcomes in Zambézia Province, Mozambique: a retrospective interrupted time series analysis

Introduction: Mentor Mothers (MM) provide peer support to pregnant and postpartum women living with HIV (PPWH) and their infants with perinatal HIV exposure (IPE) throughout the cascade of prevention of vertical transmission (PVT) services. MM were implemented in Zambézia Province, Mozambique starting in August 2017. This evaluation aimed to determine the effect of MM on PVT outcomes. Methods: A retrospective interrupted time series analysis was done using routinely collected aggregate data from 85 public health facilities providing HIV services in nine districts of Zambézia. All PPWH (and their IPE) who initiated antiretroviral therapy (ART) from August 2016 through April 2019 were included. Outcomes included the proportion per month per district of: PPWH retained in care 12 months after ART initiation, PPWH with viral suppression and IPE with HIV DNA PCR test positivity by 9 months of age. The effect of MM on outcomes was assessed using logistic regression. Results: The odds of 12-month retention increased 1.5% per month in the pre-MM period, compared to a monthly increase of 7.6% with-MM (35-61% pre-MM, 56-72% with-MM; p < 0.001). The odds of being virally suppressed decreased by 0.9% per month in the pre-MM period, compared to a monthly increase of 3.9% with-MM (49-85% pre-MM, 59-80% with-MM; p < 0.001). The odds of DNA PCR positivity by 9 months of age decreased 8.9% per month in the pre-MM period, compared to a monthly decrease of 0.4% with-MM (0-14% pre-MM, 4-10% with-MM; p < 0.001). The odds of DNA PCR uptake (the proportion of IPE who received DNA PCR testing) by 9 months of age were significantly higher in the with-MM period compared to the pre-MM period (48-100% pre-MM, 87-100% with-MM; p < 0.001). Conclusions: MM services were associated with improved retention in PVT services and higher viral suppression rates among PPWH. While there was ongoing but diminishing improvement in DNA PCR positivity rates among IPE following MM implementation, this might be explained by increased uptake of HIV testing among high-risk IPE who were previously not getting tested. Additional efforts are needed to further optimize PVT outcomes, and MM should be one part of a comprehensive strategy to address this critical need.

Immunodeficiency at antiretroviral therapy start: five-Year adult data (2012-2017) based on evolving national policies in rural mozambique

Before the 2015 implementation of "Test and Start," the initiation of combination antiretroviral therapy (ART) was guided by specific CD4 cell count thresholds. As scale-up efforts progress, the prevalence of advanced HIV disease at ART initiation is expected to decline. We analyzed the temporal trends in the median CD4 cell counts among adults initiating ART and described factors associated with initiating ART with severe immunodeficiency in Zambézia Province, Mozambique. We included all HIV-positive, treatment-naive adults (age ≥ 15 years) who initiated ART at a Friends in Global Health (FGH)-supported health facility between September 2012 and September 2017. Quantile regression and multivariable logistic regression models were applied to ascertain the median change in CD4 cell count and odds of initiating ART with severe immunodeficiency, respectively. A total of 68,332 patients were included in the analyses. The median change in CD4 cell count under "Test and Start" was higher at +68 cells/mm3 (95% CI: 57.5-78.4) compared with older policies. Younger age and female sex (particularly those pregnant/lactating) were associated with higher median CD4 cell counts at ART initiation. Male sex, advanced age, WHO Stage 4 disease, and referrals to the health facility through inpatient provider-initiated testing and counseling (PITC) were associated with higher odds of initiating ART with severe immunodeficiency. Although there were reassuring trends in increasing median CD4 cell counts with ART initiation, ongoing efforts are needed that target universal HIV testing to ensure the early initiation of ART in men and older patients.

Factors associated with loss to clinic among HIV patients not yet known to be eligible for antiretroviral therapy (ART) in Mozambique.

INTRODUCTION: Retention in HIV care prior to ART initiation is generally felt to be suboptimal, but has not been well-characterized. METHODS: We examined data on 37,352 adult pre-ART patients (ART ineligible or unknown eligibility) who enrolled in care during 2005-2008 with >1 clinical visit at 23 clinics in Mozambique. We defined loss to clinic (LTC) as >12 months since the last visit among those not known to have died/transferred. Cox proportional-hazards models were used to examine factors associated with LTC, accounting for clustering within sites. RESULTS: Of 37,352 pre-ART patients, 61% had a CD4 count within three months of enrolment (median CD4: 452, IQR: 345-611). 17,598 (47.1%) were ART ineligible and 19,754 (52.9%) were of unknown eligibility status at enrolment because of missing information on CD4 count and/or WHO stage. Kaplan-Meier estimates for LTC at 12 months were 41% (95% CI: 40.2-41.8) and 48% (95% CI: 47.2-48.8), respectively. Factors associated with LTC among ART ineligible patients included male sex (AHR(men_vs_non-pregnant women): 1.5; 95% CI: 1.4-1.6) and being pregnant at enrolment (AHR(pregnant_vs_non-pregnant women): 1.3; 95% CI: 1.1-1.5). Older age, more education, higher weight and more advanced WHO stage at enrolment were independently associated with lower risks of LTC. Similar findings were observed among patients whose ART eligibility status was unknown at enrolment. CONCLUSIONS: Substantial LTC occurred prior to ART initiation among patients not yet known to be eligible for ART, including nearly half of patients without documented ART eligibility assessment. Interventions are needed to target pre-ART patients who may be at higher risk for LTC, including pregnant women and patients with less advanced HIV disease.

Partners-based HIV treatment for seroconcordant couples attending antenatal and postnatal care in rural Mozambique: A cluster randomized trial protocol

Background: In resource-limited rural settings, scale-up of services to eliminate mother-to-child transmission of HIV has not been as effective as in better resourced urban settings. In sub-Saharan Africa, women often require male partner approval to access and remain engaged in HIV care. Our study will evaluate a promising male engagement intervention ("Homens para Saúde Mais" (HoPS+) [Men for Health Plus]) targeting the elimination of mother-to-child transmission in rural Mozambique. Design: We will use a cluster randomized clinical trial design to engage 24 health facilities (12 intervention and 12 standard of care), with 45 HIV-infected seroconcordant couples per clinic. The planned intervention will engage male partners to address social-structural and cultural factors influencing eMTCT based on new couple-centered integrated HIV services. Conclusions: The HoPS+ study will evaluate the effectiveness of engaging male partners in antenatal care to improve outcomes among HIV-infected pregnant women, their HIV-infected male partners, and their newborn children. Our objectives are to: (1) Implement and evaluate the impact of male-engaged, couple-centered services on partners' retention in care, adherence to antiretroviral therapy, early infant diagnosis uptake, and mother-to-child transmission throughout pregnancy and breastfeeding; (2) Investigate the impact of HoPS+ intervention on hypothesized mechanisms of change; and (3) Use validated simulation models to evaluate the cost-effectiveness of the HoPS+ intervention with the use of routine clinical data from our trial. We expect the intervention to lead to strategies that can improve outcomes related to partners' retention in care, uptake of services for HIV-exposed infants, and reduced MTCT.

Partners-based HIV treatment for seroconcordant couples attending antenatal and postnatal care in rural Mozambique: A cluster randomized trial protocol

Background: In resource-limited rural settings, scale-up of services to eliminate mother-to-child transmission of HIV has not been as effective as in better resourced urban settings. In sub-Saharan Africa, women often require male partner approval to access and remain engaged in HIV care. Our study will evaluate a promising male engagement intervention ("Homens para Saúde Mais" (HoPS+) [Men for Health Plus]) targeting the elimination of mother-to-child transmission in rural Mozambique. Design: We will use a cluster randomized clinical trial design to engage 24 health facilities (12 intervention and 12 standard of care), with 45 HIV-infected seroconcordant couples per clinic. The planned intervention will engage male partners to address social-structural and cultural factors influencing eMTCT based on new couple-centered integrated HIV services. Conclusions: The HoPS+ study will evaluate the effectiveness of engaging male partners in antenatal care to improve outcomes among HIV-infected pregnant women, their HIV-infected male partners, and their newborn children. Our objectives are to: (1) Implement and evaluate the impact of male-engaged, couple-centered services on partners' retention in care, adherence to antiretroviral therapy, early infant diagnosis uptake, and mother-to-child transmission throughout pregnancy and breastfeeding; (2) Investigate the impact of HoPS+ intervention on hypothesized mechanisms of change; and (3) Use validated simulation models to evaluate the cost-effectiveness of the HoPS+ intervention with the use of routine clinical data from our trial. We expect the intervention to lead to strategies that can improve outcomes related to partners' retention in care, uptake of services for HIV-exposed infants, and reduced MTCT.

Factors associated with late antiretroviral therapy initiation among adults in Mozambique.

BACKGROUND: Despite recent changes to expand the ART eligibility criteria in sub-Saharan Africa, many patients still initiate ART in the advanced stages of HIV infection, which contributes to increased early mortality rates, poor patient outcomes, and onward transmission. METHODS: To evaluate individual and clinic-level factors associated with late ART initiation in Mozambique, we conducted a retrospective sex-specific analysis of data from 36,411 adult patients who started ART between January 2005 and June 2009 at 25 HIV clinics in Mozambique. Late ART initiation was defined as CD4 count<100 cells/µL or WHO stage IV. Mixed effects models were used to identify patient- and clinic-level factors associated with late ART initiation. RESULTS: The proportion of patients initiating ART late decreased from 46% to 37% during 2005-2007, but remained constant (between 37-33%) from 2007-2009. Of those who initiated ART late (median CD4 = 57 cells/µL), 5% were known to have died and 54% were lost to clinic within 6 months of ART initiation (compared with 2% and 47% among other patients starting ART [median CD4 = 192 cells/µL]). In multivariate analysis, female sex and pregnancy at ART initiation (AOR(female_not_pregnant_vs._male) = 0.66, 95%CI [0.62-0.69]; AOR(pregnant_vs._non_pregnant) = 0.60, 95%CI [0.49-0.73]), younger and older age (AOR(15-25_vs.26-30) = 0.86, 95%CI [0.79-0.94], AOR(>45_vs.26-30) = 0.72, 95%CI [0.67-0.77]), entry into care via PMTCT (AOR(entry_through_PMTCT_vs.VCT) = 0.42, 95%CI [0.35-0.50]), marital status (AOR(married/in union_vs.single) = 0.87, 95%CI [0.83-0.92]), education (AOR(secondary_or_higher_vs.primary) = 0.87, 95%CI [0.83-0.93]) and year of ART initiation were associated with a lower likelihood of late ART initiation. Clinic-level factors independently associated with a lower likelihood of late ART initiation included CD4 machine on-site (AOR(CD4_machine_onsite_vs.offsite) = 0.83, 95%CI [0.74-0.94]) and presence of PMTCT services onsite (AOR = 0.85, 95%CI [0.77-0.93]). CONCLUSION: The risk of starting ART late remained persistently high. Efforts are needed to ensure identification and enrollment of patients at earlier stages of HIV disease. Individual and clinic level factors identified may provide clues for upstream structural interventions.

Patients enrolled in HIV care in Mozambique: baseline characteristics and follow-up outcomes.

OBJECTIVE: To utilize routinely collected service delivery data from HIV care and treatment clinics in Mozambique to describe the patient population and programmatic outcomes from 2003 to 2009. METHODS: Data from patient charts were entered into an electronic database at 28 clinics in 5 Mozambican provinces. Patients' characteristics at enrollment in HIV care and at antiretroviral therapy (ART) initiation were examined. We calculated a corrected 12-month mortality estimate using a recently developed nomogram for sub-Saharan African ART patients. RESULTS: A total of 154,188 HIV-infected individuals (10,164 children <15 years old) were enrolled in HIV care services between 2003 and 2009. Of the 51,269 (36%) adults who started ART, 35% initiated ART with CD4 count <100 cells per microliter and 14.4% with World Health Organization stage IV. Just more than 10% (10.5%) of women were documented to be pregnant at enrollment. One-third of the 3,745 (37%) children who initiated ART were <2 years old, and 53% of those <5 years initiated ART severely immunosuppressed (CD4% <15%). Thirty-five percent of all children and 30% of those initiating ART met the definition of severe malnourishment (weight-for-age Z score <-3). Among those who initiated ART, the median estimated 12-month mortality rate across sites was 13.1% (interquartile range: 11.5%-16.0%) and 13.5% (interquartile range: 11.4%-17.4%) for adults and children, respectively. CONCLUSIONS: A substantial number of HIV-infected patients have been enrolled in HIV care and initiated on ART, with many patients having advanced HIV disease. With the release of new guidelines for ART use for adults, pregnant women, and children, extensive efforts are needed to ensure more timely initiation of ART.

Factors Associated with Late Antiretroviral Therapy Initiation among Adults in Mozambique

Despite recent changes to expand the ART eligibility criteria in sub-Saharan Africa, many patients still initiate ART in the advanced stages of HIV infection, which contributes to increased early mortality rates, poor patient outcomes, and onward transmission. To evaluate individual and clinic-level factors associated with late ART initiation in Mozambique, we conducted a retrospective sex-specific analysis of data from 36,411 adult patients who started ART between January 2005 and June 2009 at 25 HIV clinics in Mozambique. Late ART initiation was defined as CD4 count<100 cells/µL or WHO stage IV. Mixed effects models were used to identify patient- and clinic-level factors associated with late ART initiation. The proportion of patients initiating ART late decreased from 46% to 37% during 2005­2007, but remained constant (between 37­33%) from 2007­2009. Of those who initiated ART late (median CD4 = 57 cells/µL), 5% were known to have died and 54% were lost to clinic within 6 months of ART initiation (compared with 2% and 47% among other patients starting ART [median CD4 = 192 cells/µL]). In multivariate analysis, female sex and pregnancy at ART initiation (AORfemale_not_pregnant_vs._male = 0.66, 95%CI [0.62­0.69]; AORpregnant_vs._non_pregnant = 0.60, 95%CI [0.49­0.73]), younger and older age (AOR15­25_vs.26­30 = 0.86, 95%CI [0.79­0.94], AOR>45_vs.26­30 = 0.72, 95%CI [0.67­0.77]), entry into care via PMTCT (AORentry_through_PMTCT_vs.VCT = 0.42, 95%CI [0.35­0.50]), marital status (AORmarried/in union_vs.single = 0.87, 95%CI [0.83­0.92]), education (AORsecondary_or_higher_vs.primary = 0.87, 95%CI [0.83­0.93]) and year of ART initiation were associated with a lower likelihood of late ART initiation. Clinic-level factors independently associated with a lower likelihood of late ART initiation included CD4 machine on-site (AORCD4_machine_onsite_vs.offsite = 0.83, 95%CI [0.74­0.94]) and presence of PMTCT services onsite (AOR = 0.85, 95%CI [0.77­0.93]). The risk of starting ART late remained persistently high. Efforts are needed to ensure identification and enrollment of patients at earlier stages of HIV disease. Individual and clinic level factors identified may provide clues for upstream structural interventions.

Determinaçao do grau de incapacidade em hansenianos nao tratados / Determination of the degree of incapacity in non-treated hansenians

Foi determinado o grau de incapacidade em 189 pacientes hansenianos virgens de tratamento, sendo 39 Tuberculóides, 16 Indeterminados, 91 Dimorfos e 43 Virchowianos. Apenas 62 (32,8%) dos pacientes apresentavam grau 0, nos 127 (67,2%) restantes, os graus I, II e III determinados indicam a necessidade de educaçao sanitária e técnicas simples de fisioterapia, para evitar a instalaçao de sequelas irreversíveis

Fatores envolvidos na reatividade do PPD em pacientes com doença de Hansen / Factors which interfere with PPD (Purified Protein Derivative) reactivity in leprosy patients

Foram testados intradermicamente com PPD (RT23 e FAP 5U) 236 pacientes hansenianos (138 multibacilares e 98 paucibacilares) e 291 contatos sadios. Observa-se um percentual menores de reatores ao PPD em pacientes multibacilares (42%), quando comparados a paucibacilares (62,2%) e contatos sadios (63,2%). Entre os pacientes multibacilares, o índice bacteriológico (IB) mostrou ser fator de interferência na resposta ao PPD, sendo significativamente maior o percentual de respondedores em pacientes com IB negativo, quando comparados aos com IB igual ou acima de 3. Foi obervado um elevado índice de positividade à tuberculina em contatos sadios (61,0%) e pacientes paucibacilares (65,3%) com teste de Mitsuda positivo

Epidemiologia da hanseníase em coorte de contatos intradomiciliares no Rio de Janeiro (1987-1991) / Leprosy epidemiology in a cohort of household contacts in Rio de Janeiro (1987-1991)

Este trabalho foi desenvolvido para estudar os fatores que influem no adoecimento dos contatos intradomiciliares de hanseníase. Foi estabelecida uma coorte de contatos intradomiciliares de hanseníase no setor de Hanseníase da Fiocruz, no Rio de Janeiro. Entre 1987 e 1991, em que foram acompanhados 670 contatos saudáveis, a taxa de incidência por pessoa-ano de follow-up foi de 0,01694. Porém, houve variação com o tempo de acompanhamento de cada indivíduo, sendo de 0,06385 ao final do primeiro ano, de 0,03299 ao final do segundo, 0,02370 ao final do terceiro, 0,018622 ao final do quarto e 0,01694 ao final do período. Foi especificado um modelo de regressão logística para os indivíduos acompanhados nos primeiros cinco anos, envolvendo 758 contatos, incluindo nessa situação os casos co-prevalentes. O risco de incidência de hanseníase está relacionado com a negatividade do teste de Mitsuda, com OR de 3,093 (IC95 percent = 1,735-5,514), com a vacinação pelo BCG, OR de 0,3802 (IC95 por cento = 0,2151-0,66719), e com a forma multibacilar do caso-índice, OR de 2,547 (IC95 por cento = 1,249-5,192). Os resultados indicam que a incidência da hanseníase em contatos está associada à forma multibacilar da doença e aos fatores imunes dos contatos

Seleção das doenças de notificação compulsória: critérios e recomendações para as três esferas de governo / Selection of obligatory notifiable diseases: criteria and recomendations for the three governmental ranges

Apresenta-se neste trabalho uma revisão referente ao Sistema Nacional de Vigilância Epidemiológica, principalmente, quanto ao processo de revisão e seleção de doenças de Notificação Compulsória. Foi elaborada uma proposta da Lista Brasileira de Doenças de Notificação Compulsória, fruto de um exercício de seleção baseado na avaliação de doenças com relação a 13 critérios e de debates com técnicos de áreas específicas do Ministério da Saúde, das Secretarias Estaduais/Municipais de Saúde, de instituições acadêmicas e da Organização Pan-Americana da Saúde. Várias recomendações são feitas, úteis para as três esferas do governo no processo de definição das doenças e agravos de notificação compulsória, levando-se em consideração o principal objetivo desse instrumento - fornecer informação de forma rápida e ágil, servir de base para a tomada de decisões e implementação de ações de controle e/ou prevenção

This paper reviews the National Epidemilogical Surveillance System, particularly the process of revision and selection of obligatory notifiable diseases. A proposal for a Brazilian List of Obligatory Notifiable Diseases was elaborated, resulting from a selection process based on the assessment of diseases against 13 criteria and on discussions with staff from specific areas of the Ministry of Health, The State and Municipal Health Secretaries and Pan-American Health Organization. The recommendations made are useful for the process of establishing the reportable diseases and conditions, taking into account the purpose of this tool to provide information in a quick and agile manner, and to serve as a basis for decision-making and for the implementation of control and/or prevention activities.

Diabetes Mellitus: revisäo dos novos critérios para diagnóstico e classificaçäo / Diabetes Mellitus recomendations for diagnosis and the new classification: a revision

Em julho de 1997, foi publicado relatório sob coordenaçäo da American Diabetes Association, contendo uma revisäo sobre definiçäo, classificaçäo e diagnóstico do diabetes melittus (DM). Os autores apresentam de forma sucinta as principais conclusöes publicadas por aquela entidade com o objetivo de divulgá-las na comunidade acadêmica, sobretudo junto aos näo endocrinologistas. No novo modelo, foi alterada a nomenclatura utilizada na descriçäo do DM e a tolerância à glicose diminuída deixou de ser classe específica de DM. Os valores da glicemia de jejum para diagnóstico de DM passaram a ser de 126mg/dl. Quando realizado o teste oral de tolerância à glicose (TOTG), säo valorizados apenas os níveis de glicemia 2 horas após a ingestäo de glicose, para diagnóstico de DM. A partir da discussäo pela comunidade médica podem surgir sugestöes e críticas a esses novos conceitos o quê, aliás, é sugerido também pela Organizaçäo Mundial de Saúde.

Estudo comparativo com dois esquemas poliquimioterápicos (duraçäo fixa) em hanseníase multibacilar - seguimento de 50.32 (mais ou menos) 19.62 e 39.70 (mais ou menos) 19.47 meses / Comparative study with two scheme multidrug therapy ( fixed dosage) in multibacillar leprosy - occurrence of 50.32 (more or less) 19.62 and 39.70 (more or less) 19.47 months

Estudo comparativo de evoluçäo clínica e baciloscópica de 140 casos de hanseníase classificados como multibacilares, divididos em dois grupos e submetidos a dois tratamentos com associaçäo de quimioterápicos com duraçäo fixa. Grupo I: 70 casos submetidos a Rifampicina (RFM) 600 mg e Dapsona (DDS) 100 mg diários auto administrados por 3 meses consecutivos seguidos de DDS - 100 mg diários auto administrados por 21 meses. Grupo II: RFM - 600 mg e Clofazimina (CFZ) 300 mg uma vêz ao mês, supervisionados, associados a DDS - 100 mg e CFZ 50 mg diários, auto administrados com duraçäofixa de 24 doses supervisionadas. Näo foram encontradas diferenças significativas (p > 0.05) na evoluçäo baciloscópica e neuromotora entre os grupos, na vigência dos tratamentos e no seguimento pós alta cura. Foi encontrada difrença estatística (p < 0.05) na ocorrência de manifestaçöes reacionais tendo o Grupo I apresentado maior número de casos com reaçäo durante o tratamento e pós alta. Esta diferença foi atribuida a presença da CFZ no esquema terapêutico do Grupo II. O follow-up total do grupo I foi de 2.110/pacientes ano com média de 50.32(mais ou menos) 19.62 meses sendo diagnosticado dois casos de recidiva. Em 1 dos casos procedeu-se a inoculaçäo da biópsia cutânea para inoculaçäo no coxim plantar do camundongo de acordo com Shepard para verificaçäo da viabilidade bacilar e rsistência a RFM e DDS. Os resultados demonstraram bacilos viáveis, susceptíveis as drogas testadas. Este resultado foi confirmado pela evoluçäo clínica e baciloscópica do caso após introduçäo no esquema poliquimioterápico preconizado pela OMS. Para o Grupo II, submetido ao esquema preconizado pela OMS e o atual em vigência em nosso país, o seguimento total foi de 1.897/pacientes ano, média 39.70 (mais ou menos) 19.47 meses näo tendo sido diagnosticada nenhuma recidiva

Efeito protetor do BCG intradérmico em contatos de pacientes de hanseníase: estudo de caso-controle / The protective effect of BCG intradermal vaccination in contacts of leprosy patients: a case-control study

O presente estudo se propôs a determinar o efeito protetor da vacinação intradérmica com BCG (bacilodeCalmette-Guérin) em contatos de pacientes de hanaseníase através do desenho de estudo caso-controle.Selecionou-se 65 casos e 904 controles, de zero a 29 anos de idade, provenientes de uma população base de contatos de pacientes de hanseníase residentes no Município e Área Metropolitando do Rio de Janeiro (área endêmica de hanseníase). De ambos os grupos obtiveram-se informações quanto a exposição ao BCG (presença ou ausência de cicatriz vacinal), idade, sexo, tipo de contato, parentesco e forma clínica,bacterioscopia, Mitsuda e grau de incapacidade. Realizou-se análise não pareada dos dados onde a presença de cicatriz de BCG mostrou-se negativamente associada com hanseníase indicando uma eficácia protetora de 59% (95% I.C. = 29% - 77%). A análise estratificada não revelou que as variáveis idade, sexo, tipo de contato, parentesco e forma clínica do caso primário introduziram confusão na avaliação da eficácia vacinal.Discute-se a adequação do desenho de estudo tipo caso-controle para a avaliação de eficácia vacinal em doença crônica, as implicações dos resultados e sua importância para a atividade de vigilância de contatos no Programa de Controle da Hanseníase.